Anna Locasciulli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Locasciulli has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Jakob Passweg
University Hospital Basel, Basel, Switzerland
3 shared publications Andrea Bacigalupo
II Divisione Ematologia e Trapianto di Midollo, Ospedale San Martino, Genova, Italy
2 shared publicationsBarbara Bruno
II Divisione Ematologia e Trapianto di Midollo, Ospedale San Martino, Genova, Italy
2 shared publicationsBarbara Montante
Ematologia Pediatrica e Trapianto di Midollo,Ospedale San Camillo, Roma
2 shared publicationsA. Bacigalupo
1 shared publicationA. Bekassy
1 shared publication
Latest Publications
- 20 May 2010
- Published by Wiley in British Journal of Haematology
- Vol. 149 (6) , 890-895
Hepatitis‐associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party
Summary: In order to assess the epidemiology of Hepatitis‐Associated Aplasia (HAA) and compare treatment outcome of HAA with non‐HAA patients, we evaluated 3916 aplastic anaemia patients reported to the European Registry between 1990 and 2007. Year, month, season of diagnosis, type and outcome of first‐line therapy were analysed. Prevalence of HAA (n = 214) in Europe was 5%. Compared to non‐HAA patients, HAA patients were younger (15 vs. 20 years, P < 0·001), with a male prevalence (68% vs. 58%P = 0·002), and were treated earlier after diagnosis (46 vs. 62 d; P < 0·001). No significant differences were found regarding the year or month of diagnosis. No geographic clusters could be identified. Actuarial survival at 10 years after first‐line immunosuppression was 69%, and did not differ according to aetiology. The 10‐year actuarial survival after transplantation was 70%, and was comparable in HAA and non‐HAA patients, when stratified for age and donor type. In a multivariate Cox analysis, increasing age and delayed treatment were significant negative indicators for survival. In conclusion, the incidence of HAA was 5% and was evenly distributed over time and geographic areas in Europe. Treatment outcome and predictive variables, were comparable in patients with or without HAA.
- 20 May 2010
- Published by Wiley in British Journal of Haematology
- Vol. 149 (6) , 890-895
Hepatitis‐associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party
Summary: In order to assess the epidemiology of Hepatitis‐Associated Aplasia (HAA) and compare treatment outcome of HAA with non‐HAA patients, we evaluated 3916 aplastic anaemia patients reported to the European Registry between 1990 and 2007. Year, month, season of diagnosis, type and outcome of first‐line therapy were analysed. Prevalence of HAA (n = 214) in Europe was 5%. Compared to non‐HAA patients, HAA patients were younger (15 vs. 20 years, P < 0·001), with a male prevalence (68% vs. 58%P = 0·002), and were treated earlier after diagnosis (46 vs. 62 d; P < 0·001). No significant differences were found regarding the year or month of diagnosis. No geographic clusters could be identified. Actuarial survival at 10 years after first‐line immunosuppression was 69%, and did not differ according to aetiology. The 10‐year actuarial survival after transplantation was 70%, and was comparable in HAA and non‐HAA patients, when stratified for age and donor type. In a multivariate Cox analysis, increasing age and delayed treatment were significant negative indicators for survival. In conclusion, the incidence of HAA was 5% and was evenly distributed over time and geographic areas in Europe. Treatment outcome and predictive variables, were comparable in patients with or without HAA.
- Open Access
- 1 January 2009
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 1 (3) , e2009016
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
- 1 January 2009
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 1 (3) , e2009016
Open AccessHEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
- 1 June 2008
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 12, S20
Long-term Follow-up of HCV Infected Patients; Updated Results of the EBMT Prospective Study
- 1 June 2008
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 12, S20
Long-term Follow-up of HCV Infected Patients; Updated Results of the EBMT Prospective Study
- 1 January 2007
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 92 (1) , 11-18
Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation
The treatment of acquired aplastic anemia (AA) is based on allogeneic bone marrow transplantation (BMT) and immunosuppressive therapy. The aim of this study was to assess the outcome of children and adults with AA treated in the last decade, and to determine whether results have improved in two sequential time periods,1991-1996 and 1997-2002. Two-thousands and seventy-nine consecutive patients with AA, classified according to first-line treatment: BMT (n=1567) or immunosuppressive therapy (n= 912), the patients for the two sequential time periods were studied. Analyses included variables related to patients, disease and transplant. The actuarial 10-year survival was 73% and 68% for BMT or immunosuppressive treatment, respectively (p=0.002). BMT outcome improved significantly with time (69% and 77%, p=001) for both matched sibling donor (MSD) (74% and 80%; p=0.003 ), alternative donor (38% and 65% p=0.0001), and was better in children (79% versus 68%, p or =16 years (p=0.0009), longer interval between diagnosis -treatment (p=0.04), single drug versus combined IS (p=0.02). Outcome has improved in subsets of AA patients: those receiving first- line BMT and children with vSAA treated with IS. Age remains a major predictor for both treatments. Early intervention is associated with a significantly better outcome and is strongly recommended, whatever the first-line therapy.
- 1 January 2007
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 92 (1) , 11-18
Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation
The treatment of acquired aplastic anemia (AA) is based on allogeneic bone marrow transplantation (BMT) and immunosuppressive therapy. The aim of this study was to assess the outcome of children and adults with AA treated in the last decade, and to determine whether results have improved in two sequential time periods,1991-1996 and 1997-2002. Two-thousands and seventy-nine consecutive patients with AA, classified according to first-line treatment: BMT (n=1567) or immunosuppressive therapy (n= 912), the patients for the two sequential time periods were studied. Analyses included variables related to patients, disease and transplant. The actuarial 10-year survival was 73% and 68% for BMT or immunosuppressive treatment, respectively (p=0.002). BMT outcome improved significantly with time (69% and 77%, p=001) for both matched sibling donor (MSD) (74% and 80%; p=0.003 ), alternative donor (38% and 65% p=0.0001), and was better in children (79% versus 68%, p or =16 years (p=0.0009), longer interval between diagnosis -treatment (p=0.04), single drug versus combined IS (p=0.02). Outcome has improved in subsets of AA patients: those receiving first- line BMT and children with vSAA treated with IS. Age remains a major predictor for both treatments. Early intervention is associated with a significantly better outcome and is strongly recommended, whatever the first-line therapy.
- 1 September 2004
- Vol. 89 (9) , 1054-61
Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study.
In a previous study we showed that patients with severe aplastic anemia (SAA) treated with anti-lymphocyte globulin (ALG), cyclosporin (CyA) and granulocyte colony-stimulating factor (G-CSF) 5 micro g/kg/day had an encouraging outcome. However, failure to respond, delayed responses, partial responses, relapses and early deaths remain significant problems. The aim of the present study was to test whether a higher dose of G-CSF (10 micro g/kg/day) would reduce these complications. This was a multicenter prospective trial in 77 SAA patients treated with horse ALG (15 mg/kg/day day1-5) and CyA (5 mg/kg/day day 1-180). Patients were randomized to receive G-CSF 5 micro g/kg/day (n=38, group A) or 10 micro g/kg/day (n=39, group B) from day +1 to day +30. All patients then received G-CSF 5 micro g/kg/day from day +31 to day +90. The primary end point of this study was response at day +120. Secondary end points were early deaths, blood counts at day +120, and survival. At day +120 responses were classified as absent, partial, and complete in 12, 22, and 4 patients in group A and in 23, 7, and 9 patients in group B (p=0.001). At last follow-up these figures were respectively 9, 12, and 17 vs 19, 2, and 18 (p=0.004). Thirteen patients (5 in group A and 8 in group B) died before day 120 (p=0.3). Median peripheral blood counts on day 120 were comparable in the two groups: Hb 10.5 and 9.5 g/dL in group A and B, respectively (p=0.6), Neutrophil counts were 2.4 vs 1.9x10(9)/L in groups A and B (p=0.4) and platelet counts were, respectively, 42 vs 36x10(9)/L (p=0.3). The actuarial survival at 4 years is 72% in group A and 67% in group B (p=0.3). Increasing the dose of G-CSF does not appear to reduce early deaths, does not improve peripheral blood counts nor survival, and may reduce the response rate in patients with SAA receiving ALG and CyA.
- 1 September 2004
- Vol. 89 (9) , 1054-61
Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study.
In a previous study we showed that patients with severe aplastic anemia (SAA) treated with anti-lymphocyte globulin (ALG), cyclosporin (CyA) and granulocyte colony-stimulating factor (G-CSF) 5 micro g/kg/day had an encouraging outcome. However, failure to respond, delayed responses, partial responses, relapses and early deaths remain significant problems. The aim of the present study was to test whether a higher dose of G-CSF (10 micro g/kg/day) would reduce these complications. This was a multicenter prospective trial in 77 SAA patients treated with horse ALG (15 mg/kg/day day1-5) and CyA (5 mg/kg/day day 1-180). Patients were randomized to receive G-CSF 5 micro g/kg/day (n=38, group A) or 10 micro g/kg/day (n=39, group B) from day +1 to day +30. All patients then received G-CSF 5 micro g/kg/day from day +31 to day +90. The primary end point of this study was response at day +120. Secondary end points were early deaths, blood counts at day +120, and survival. At day +120 responses were classified as absent, partial, and complete in 12, 22, and 4 patients in group A and in 23, 7, and 9 patients in group B (p=0.001). At last follow-up these figures were respectively 9, 12, and 17 vs 19, 2, and 18 (p=0.004). Thirteen patients (5 in group A and 8 in group B) died before day 120 (p=0.3). Median peripheral blood counts on day 120 were comparable in the two groups: Hb 10.5 and 9.5 g/dL in group A and B, respectively (p=0.6), Neutrophil counts were 2.4 vs 1.9x10(9)/L in groups A and B (p=0.4) and platelet counts were, respectively, 42 vs 36x10(9)/L (p=0.3). The actuarial survival at 4 years is 72% in group A and 67% in group B (p=0.3). Increasing the dose of G-CSF does not appear to reduce early deaths, does not improve peripheral blood counts nor survival, and may reduce the response rate in patients with SAA receiving ALG and CyA.
- 11 November 1999
- Published by Cambridge University Press (CUP)
Aplastic Anemia
This book takes account of the most recent findings in laboratory research and clinical trials to provide a comprehensive and up-to-date reference on the pathophysiology, epidemiology, diagnosis and treatment of acquired and inherited aplastic anemia. As well as a detailed overview of the pathophysiology of the disease, the international team of authors cover all aspects of management, including the established approaches of bone marrow transplantation and immunosuppressive treatment, new approaches such as the use of hematopoietic growth factors and escalated immunosuppression, and controversial issues such as stem cell transplantation. Also included is an important international consensus document on treatment, and a final section concentrates on the inherited syndrome Fanconi's anemia. Detailed treatment guidelines are given, making this the definitive resource for hematologists and other clinicians involved in the management and supportive care of patients with aplastic anemia. Scientists interested in bone marrow failure will also find this an invaluable reference.
- 11 November 1999
- Published by Cambridge University Press (CUP)
Aplastic Anemia
This book takes account of the most recent findings in laboratory research and clinical trials to provide a comprehensive and up-to-date reference on the pathophysiology, epidemiology, diagnosis and treatment of acquired and inherited aplastic anemia. As well as a detailed overview of the pathophysiology of the disease, the international team of authors cover all aspects of management, including the established approaches of bone marrow transplantation and immunosuppressive treatment, new approaches such as the use of hematopoietic growth factors and escalated immunosuppression, and controversial issues such as stem cell transplantation. Also included is an important international consensus document on treatment, and a final section concentrates on the inherited syndrome Fanconi's anemia. Detailed treatment guidelines are given, making this the definitive resource for hematologists and other clinicians involved in the management and supportive care of patients with aplastic anemia. Scientists interested in bone marrow failure will also find this an invaluable reference.